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https://doi.org/10.1186/s13148-018-0561-5RESEARCH Open AccessT cell epigenetic remodeling and
accelerated epigenetic aging are linked to
long-term immune alterations in childhood
cancer survivors
Sara Daniel1, Vibe Nylander2, Lars R. Ingerslev2, Ling Zhong3, Odile Fabre2, Briana Clifford1, Karen Johnston4,
Richard J. Cohn4, Romain Barres1,2*† and David Simar1,2*†Abstract
Background: Cancer treatments have substantially improved childhood cancer survival but are accompanied by
long-term complications, notably chronic inflammatory diseases. We hypothesize that cancer treatments could lead
to long-term epigenetic changes in immune cells, resulting in increased prevalence of inflammatory diseases in
cancer survivors.
Results: To test this hypothesis, we established the epigenetic and transcriptomic profiles of immune cells from 44
childhood cancer survivors (CCS, > 16 years old) on full remission (> 5 years) who had received chemotherapy alone
or in combination with total body irradiation (TBI) and hematopoietic stem cell transplant (HSCT). We found that
more than 10 years post-treatment, CCS treated with TBI/HSCT showed an altered DNA methylation signature in T
cell, particularly at genes controlling immune and inflammatory processes and oxidative stress. DNA methylation
remodeling in T cell was partially associated with chronic expression changes of nearby genes, increased frequency
of type 1 cytokine-producing T cell, elevated systemic levels of these cytokines, and over-activation of related signaling
pathways. Survivors exposed to TBI/HSCT were further characterized by an Epigenetic-Aging-Signature of T cell consistent
with accelerated epigenetic aging. To investigate the potential contribution of irradiation to these changes,
we established two cell culture models. We identified that radiation partially recapitulated the immune
changes observed in survivors through a bystander effect that could be mediated by circulating factors.
Conclusion: Cancer treatments, in particular TBI/HSCT, are associated with long-term immune disturbances.
We propose that epigenetic remodeling of immune cells following cancer therapy augments inflammatory-
and age-related diseases, including metabolic complications, in childhood cancer survivors.
Keywords: Epigenetic aging, DNA methylation, inflammation, cancer survivors, T cellBackground
Improvement in the cure rate of childhood cancer, and
in particular acute lymphoblastic leukemia, has led to a
significant increase in the number of long-term survivors
[1]. However, more than 95% of childhood cancer survi-
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(http://creativecommons.org/publicdomain/zeof 45 [2]. The most frequently reported complications
include cardiac, endocrine, or neurological conditions
[3], chronic diseases that all share an inflammatory com-
ponent. While a combination of cancer treatment, life-
style and environmental factors could contribute to the
development of these chronic conditions [4, 5], we and
others have identified total body irradiation (TBI) and
hematopoietic stem cells transplant (HSCT) as major
risk factors for the development of metabolic, cardiovas-
cular, and other health conditions in childhood cancer
survivors [6, 7]. When compared to chemotherapy alone,le is distributed under the terms of the Creative Commons Attribution 4.0
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cidence of several chronic health conditions 20 years
post-diagnosis, with TBI being the mode of radiation
causing the highest incidence of severe conditions [3].
We further reported in a cohort of 248 CCS that the
prevalence of metabolic complications was more than
doubled at a median of 12.7 years after remission [7].
More recently, we have established in a mouse model
that irradiation in the absence of HSCT led to altered
muscle and adipose lineage commitment and metabolic
dysfunction later in life [8].
Immune disturbances contribute to cardiovascular,
neurological, and metabolic conditions, notably in early
development of these diseases [9, 10]. Radiation-induced
immune response, including macrophage activation, neu-
trophil, and lymphocyte recruitment, leads to the produc-
tion of pro-inflammatory mediators to support anti-tumor
activity and clearance of apoptotic cells [11, 12], with a
similar response having been described in response to
chemotherapy [13]. Although this inflammatory process is
usually confined to the acute phase of the radiation
response [14], long-term immune changes could also
persist following irradiation, chemotherapy, or HSCT [15,
16]. As there is still limited evidence to support the exist-
ence of long-term chronic inflammation, the mechanisms
responsible for long-term chronic immune disturbances in
cancer survivors and their potential consequences on
survivors’ health still remain unknown.
We hypothesized that childhood cancer survivors, in
particular when exposed to TBI/HSCT, present long-
lasting immune alterations that could contribute to dis-
eases later in life. Our results show that exposure to TBI/
HSCT is associated with persistent chronic inflammation,
a remodeling of immune cells epigenome and altered im-
mune functions. We further establish that T cell from
childhood cancer survivors presents an epigenetic signa-
ture consistent with accelerated aging. We propose that
persistent alterations of the immune system in childhood
cancer survivors contributes to higher risk of secondary
diseases, including cardio-metabolic diseases.Results
To study the long-term effect of cancer treatment on im-
mune functions, we recruited childhood cancer survivors
who had received chemotherapy alone or in combination
with TBI/HSCT in the course of their treatment, with clin-
ical characteristics and cancer history presented in Table 1.
The majority of our population was composed of survivors
of acute lymphoblastic or myeloid leukemia, as well as
Hodgkin’s and non-Hodgkin’s lymphoma, and all survivors
received chemotherapy. Our two groups were age-matched,
with no difference in age at inclusion, at diagnosis, or in
number of years on remission (Table 1). Survivors in theTBI/HSCT group tended to be shorter and lighter (p = 0.05
and p = 0.07 respectively).
TBI/HSCT is associated with long-term epigenetic
remodeling in T cell
Reports have suggested that inflammation could persist
years after cancer treatments [17], potentially through a
long-term “memory” of the treatment, implying epigenetic
mechanisms. Thus, we assessed the DNA methylation
profile of immune cells. CD4+ (p = 0.05) and CD8+ T cell
(p = 0.07) tended to show lower global DNA methylation
levels in CCS treated with TBI/HSCT, while monocytes
tended to show higher methylation levels (p = 0.06), with
no difference in other populations (Fig. 1a). We then tested
if these changes in methylation were gene-specific and per-
formed reduced representation bisulfite sequencing (RRBS)
in CD4+ T cell. We found differential methylation at cyto-
sines which corresponded to 419 different neighboring
genes in the TBI/HSCT group (Fig. 1b, Additional file 1:
Table S1). Out of the 419 differentially methylated regions
(DMRs), 9 were identified in enhancers and 47 in
promoters (Additional file 1: Table S1). Differential methy-
lation was also found at microRNA (miRNA) loci (Add-
itional file 1: Table S1), including miR-942 and miR-378c,
which have been implicated in acute response to irradi-
ation, or miR-124 which is linked to T cell polarization and
inflammation [18, 19]. Using GO analysis on our 419 cod-
ing genes containing differentially methylated cytosines, we
identified enrichments for GO terms linked to oxidative
stress (15/77 GO terms found in our data, Fig. 1c, Add-
itional file 1: Table S2) and genes related to immune pro-
cesses (21/77 terms) including positive and negative
regulation of cytokines production (Fig. 1c, Additional file 1:
Table S2). Transcriptomic analysis of CD4+ T cell by
RNA-seq returned a small subset of genes differentially
expressed (29, Fig. 1d, Additional file 1: Table S3a). Al-
though we did not detect differential methylation at the
proximity of the differentially expressed genes, except for
adhesion G protein-coupled receptor G1 (also known as
GPR56), we found enrichment for GO terms related to
inflammation, similar to the DMR-associated genes (Fig. 1e,
Additional file 1: Table S3B). Collectively, these results sup-
port that TBI/HSCT stably alters the epigenome of T cell.
Cancer survivors treated with TBI/HSCT show long-term
altered immune function
To determine the consequences of the remodeling of the
T cell epigenome, we analyzed T cell function (Fig. 2a).
In mitogen-stimulated CD4+ and CD8+ T cell from the
TBI/HSCT group, we found a greater frequency of inter-
feron (IFN)-γ but not interleukin (IL)-4-producing cells
(Fig. 2b, Additional file 1: Figure S1a). Intracellular
signaling pathways, including mTOR (mammalian target
of rapamycin) and MAPK (mitogen-activated protein
Table 1 Participants’ characteristics
Non-IRR TBI/HSCT p value
(TBI/HSCT
vs non-IRR)
Number of participants 30 14
Sex (male/female) 15/15 9/5 0.25
Age (year, range) 22.1 (16–34) 25.1 (16–39) 0.48
Age at diagnosis (year, range) 7.2 (0.2–17.7) 7.7 (1.2–16.6) 0.78
Height (cm) 170 ± 9 163 ± 12 0.05
Weight (kg) 73.9 ± 18.8 62.0 ± 19.3 0.07
Body mass index (kg/m2) 25.5 ± 5.7 23.2 ± 6.8 0.26
Waist-to-height ratio 50.8 ± 8.5 51.4 ± 11.1 0.84
Diagnosis (number of survivors, %)
Acute lymphoblastic leukemia 12 (40%) 5 (36%)
Relapse 0 (0%) 1 (7%)
Acute myeloid leukemia 1 (3%) 6 (43%)
Relapse 0 (0%) 1 (7%)
Neuroblastoma 1 (3%) 2 (14%)
Malignant histiocytosis 0 (0%) 1 (7%)
Hodgkins lymphoma 2 (13%) 0 (0%)
Non-Hogkins lymphoma 3 (10%) 0 (0%)
Other type of cancer 11 (21%) 0 (0%)
Treatments (number of survivors, %)
Chemotherapy 30 (100%) 14 (100%)
TBI 0 (0%) 14 (100%)
Hematopoietic stem cell transplant 3 (10%) 14 (100%)
Triglycerides (mmol/l) 1.03 ± 0.50 2.11 ± 2.08 0.01
Total cholesterol (mmol/l) 4.82 ± 0.79 5.14 ± 1.12 0.28
LDL-cholesterol (mmol/l) 2.86 ± 0.53 2.97 ± 1.13 0.67
HDL-cholesterol (mmol/l) 1.59 ± 0.71 1.17 ± 0.41 0.05
Glucose (mmol/l) 4.74 ± 0.47 6.04 ± 4.19 0.10
Insulin (mIU/l) 7.17 ± 5.76 11.3 ± 8.60 0.07
HOMA-IR 0.96 ± 0.73 1.84 ± 1.98 0.04
LDL low-density lipoprotein, HOMA-IR homeostatic model assessment insulin resistance index, Non-IRR non-irradiated, TBI total body irradiation, HSCT
hematopoietic stem cell transplant
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cytokines production (Fig. 2a). Quantification of p38,
ribosomal protein S6 kinase1 (S6 k1), c-Jun N-terminal
kinase (JNK) and Akt phosphorylation in CD4+ and
CD8+ T cell showed a marked increase for all four pro-
teins in both groups upon mitogen stimulation (Fig. 2c,
Additional file 1: Figure S1b). However, the TBI/HSCT
group showed over-activation of p38 and S6 k1 under
resting conditions in CD4+ (Fig. 2c) and CD8+ cells
(Additional file 1: Figure S1b), potentially linked to the
increased frequency of type 1 cytokine-producing T cell.
These functional changes in T cell from the TBI/HSCT
group were associated with elevated systemic levels of
IFN-γ and tumor necrosis factor (TNF)-α (p < 0.05,Fig. 2d), suggesting a link between radiation, HSCT, and
long-term inflammation.
Acute exposure to radiation triggers a transient stress
response resulting in pro-inflammatory cytokines pro-
duction [14]. Thus, we tested the contribution of direct
irradiation to T cell polarization and MAPK/mTOR acti-
vation using an in vitro model (Fig. 3a). Direct irradi-
ation did not affect p-p38 or pS6 k1 (p > 0.05, Fig. 3b),
or pJNK, pAkt-Ser473, and the frequency of IL-4/
IFN-γ-producing cells in Jurkat cells (Additional file 1:
Figure S2a-b). We then investigated the indirect effect of
irradiation by exposing mitogen-stimulated PBMCs
collected from healthy donors to the conditioned media
obtained from irradiated fibroblasts (Fig. 3c). We found
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Fig. 1 Epigenetic and transcriptomic analysis of T cell in childhood cancer survivors (CCS). a. No difference in global DNA methylation was observed in
total lymphocytes or B cells (CD3−CD21+) between CCS who received total body irradiation and hematopoietic stem cell transplant (TBI/HSCT)
compared to those who received no irradiation (non-IRR, p > 0.05). CD4+ cells from CCS treated with TBI/HSCT showed global hypomethylation (p =
0.05), with a similar trend in CD8+ cells (p = 0.07), whereas monocytes tended to show hypermethylation (p = 0.06). b. Volcano plot representing the
distribution of differentially methylated genes in the two groups of survivors, with more than 400 genes differentially methylated (represented in red,
with a difference in methylation of more than 25%). c. Sankey diagram showing representative Gene Ontology (GO) terms clusters from differentially
methylated genes, including all main GO terms related to immunological processes or oxidative stress. The width of the arrow is proportional to the
contribution of the gene to the GO term and to the contribution of the GO term to immunological processes or oxidative stress d. Volcano plot
reflecting the distribution of differentially expressed genes (in red) between the two groups of CCS. e. Representative GO terms clusters from
differentially expressed genes showed a particular enrichment in GO terms related to immune processes and oxidative stress. f. Predicted biological
age based on methylation levels on three specific CpG sites on ASPA, ITGA2B, and PDE4C was higher in CCS treated with TBI/HSCT. Both groups
showed increased distance from the regression line, suggesting increased biological predicted age compared to chronological age. Chronological age
was not different between the donors and the children who received hematopoietic stem cells transplant at the time of the experiment (p > 0.05)
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Fig. 2 CD4+ T cell is altered in childhood cancer survivors (CCS) treated with TBI (total body irradiation)/HSCT (hematopoietic stem cell
transplant). a. Schematic representation of intracellular signaling involved in polarized activation in T cells. b. Representative FACS dot plot of
CD4+ cells producing interferon (IFN)-γ (X-axis) or interleukin (IL)-4 (Y-axis) in CCS treated with TBI/HSCT (bottom) or no irradiation (non-IRR, top).
The frequency of CD4+ cells producing IFN-γ was higher in CCS treated with TBI/HSCT compared to non-IRR CCS (p < 0.01), with no difference in
CD4+ cells producing IL-4 (p = 0.3). c. Representative histograms for phosphorylated p38, phosphorylated ribosomal protein S6 kinase 1 (pS6 k1),
phosphorylated c-Jun N-terminal kinase (pJNK), and phosphorylated Akt on Ser473 under resting condition (Rest) and upon mitogen stimulation
(Stim). Upon mitogen stimulation, p-p38, pS6k1, pJNK, and pAkt Ser473 were all significantly increased (*p < 0.05, compared to resting condition)
in CD4+ cells in both groups (n = 10 in each group). Higher resting phosphorylation levels of p38 and S6 k1 were observed in CD4+ cells from
CCS treated with TBI (p = 0.02 and p = 0.04 respectively). d. Plasma levels of Th1 cytokines including interferon (IFN)-γ and tumor necrosis factor
(TNF)-α were significantly elevated in CCS treated with TBI/HSCT (p < 0.01 and p = 0.04 respectively) whereas interleukin (IL)-10 and IL-13, or IL-2
and IL-12, did not differ between the two groups (p > 0.05)
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dose of 3Gy increased phosphorylation of p38 and S6 K1
in CD4+ cells (Fig. 3d) but had no effect on pJNK or
pAkt-Ser473 (Additional file 1: Figure S2c). Exposure to
conditioned media from fibroblasts irradiated with a
dose of 3Gy also had no effect on the frequency of CD4+cells or CD8+ cells producing IFN-γ (p = 0.14, Fig. 3d) or
IL-4 (p > 0.05, Fig. 3d, Additional file 1: Figure S3a-b for
CD8+ cells). These results suggest that irradiation may
exert its effect on T cell through secreted factors. To
identify proteins secreted by irradiated cells, we analyzed
cell culture supernatants from irradiated (1) fibroblasts
ab
c
d
Fig. 3 Intracellular signaling pathways involved in T cell polarization are activated by irradiation through a bystander mechanism. a. Schematic
representation of the in vitro model to investigate the direct effect of irradiation on a T cell line (Jurkat cells). b. No effect of irradiation (0 to 6Gy)
was observed on the activation of p38 or ribosomal protein S6 kinase 1 (S6 k1) in Jurkat cells (p > 0.05). c. Schematic representation of the co-
culture model used to investigate the indirect effect of irradiation on the activation of intracellular signaling pathways involved in T cell
polarization. d. In CD4+ cells, pre-incubation with culture media obtained from irradiated adipocytes with a dose of 3Gy resulted in higher
phosphorylation levels of both p38 and S6 k1 (*p < 0.05, **p < 0.01, ***p < 0.001). No effect of the pre-incubation in culture media from irradiated
adipocytes was observed on the percentage of CD4+ producing interferon (IFN)-γ or interleukin (IL)-4 although a trend towards an overall effect
was observed on the frequency of IFN-γ producing CD4+ cells (p = 0.12)
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post-exposure using mass spectrometry (Fig. 4a). Most
detected proteins were secreted in both irradiated or
non-irradiated conditions (Fig. 4b), with some proteins
uniquely detected in the irradiated or non-irradiated
conditions, although this did not reach statistical signifi-
cance (Additional file 1: Table S4). We next analyzed
plasma samples from CCS and detected more than 50
proteins with a distinct expression pattern (Fig. 4c). GO
analysis identified a specific enrichment for pathways re-
lated to cell stress, immune processes and inflammation
(Fig. 4d). Of interest, the alpha-1-antitrypsin protein
(encoded by the SERPINA1 gene) was decreased in the
TBI/HSCT group. Given the role of alpha-1 antitrypsin
in the inhibition of pro-inflammatory cytokines secretion
[20], decreased levels of this protein could participate in
the immune changes in CCS treated with TBI/HSCT.
Our cluster analysis suggested that the expression pat-
tern of these proteins was group-specific. Collectively,
our data suggest that secreted factors participate in along-term alteration of the immune system in survivors
exposed to irradiation and hematopoietic stem cell
transplant.
Childhood cancer survivors are characterized by
accelerated epigenetic aging
Given that T cell epigenetic remodeling specifically
affected genes involved in inflammation and oxidative
stress, two processes associated with aging, we
investigated the contribution of epigenetic factors in
cancer treatment-induced accelerated aging. Using the
Epigenetic-Aging-Signature method [21], we found that
both groups of survivors had increased predicted bio-
logical age (Fig. 1f ), with CCS treated with TBI/HSCT
showing a higher predicted biological age (p = 0.01,
Fig. 1f ). Moreover, the chronological age was correlated
to the predicted age in non-irradiated CCS (n = 8, r =
0.85, p < 0.01, Fig. 1f ) but not in the TBI/HSCT group
(n = 7, p > 0.05, Fig. 1f ). Since all survivors treated with
TBI also received HSCT, our results could indicate that
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BP establishment of localization GO:0051234 5196 47 32 1.19e-05 A e M D D A e e A D A S A Ba Ba Ba Ba ? A e M D D A S A A A e A D D e
BP transport GO:0006810 5095 47 32 7.04e-06 A e M D D A e e A D A S A Ba Ba Ba Ba ? A e M D D A S A A A e A D D e
BP import into cell GO:0098657 793 47 15 8.41e-07 A e A D D e S A Ba Ba Ba Ba ? e S D
BP vesicle-mediated transport GO:0016192 1949 47 27 3.81e-12 A A D D A e A A A S A Ba Ba Ba Ba ? A e S A A A A A A A D A
BP endocytosis GO:0006897 732 47 14 3.27e-06 A A D D e S A Ba Ba Ba Ba ? e S D
BP phagocytosis GO:0006909 320 47 7 3.15e-02 A S Ba Ba Ba Ba ? S
BP membrane invagination GO:0010324 102 47 6 4.65e-04 S Ba Ba Ba Ba ? S
BP plasma membrane invagination GO:0099024 94 47 6 2.85e-04 S Ba Ba Ba Ba ? S
BP phagocytosis, engulfment GO:0006911 85 47 6 1.56e-04 S Ba Ba Ba Ba ? S
BP exocytosis GO:0006887 844 47 12 1.57e-03 A A A ? A A A A A A A A A
BP regulated exocytosis GO:0045055 734 47 12 3.50e-04 A A A ? A A A A A A A A A
BP platelet degranulation GO:0002576 124 47 8 1.61e-06 ? A A A A A A A A
BP very-low-density lipoprotein particle clearance GO:0034447 9 47 3 3.11e-03 A D D ?
ba c
d
Fig. 4 (See legend on next page.)
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Fig. 4 Circulating factors involved on the indirect effect of irradiation on T cell function a. Schematic representation of the in vitro model to
identify circulating factors responsible for the indirect effect of irradiation on T cell function. b. Venn diagram representing uniquely identified
proteins in culture media from non-irradiated cells (0Gy, light green), from irradiated cells (3Gy, red), or in both conditions (dark green), in four
different conditions (undifferentiated and differentiated fibroblasts at 24 h and seven days post-irradiation). c. Venn diagram representing
uniquely identified proteins in plasma from non-irradiated (non-IRR, light green) or TBI/HSCT-treated survivors (TBI/HSCT, red), or found in both
groups (dark green). Unsupervised hierarchical cluster analysis of protein abundance identifying specific patterns of proteins abundance profile in
the two groups of survivors. d. Gene ontology analysis performed on proteins showing a different pattern of abundance between the two
groups of survivors. S: Sequence or structural similarity [ISS]; Ba: biological aspect of ancestor [IBA]; A: traceable author [TAS]; e: electronic
annotation [IEA]; D: direct assay [IDA]; M: mutant phenotype [IMP]; G: genetic interaction [IGI]; a: non-traceable author [NAS]; X: expression
pattern [IEP]
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as previously suggested [21]. However, we did not find
any difference between the donors’ and the recipients’
chronological age (Fig. 1f ). In addition, the inclusion of
the donors’ age in the model did not change the correl-
ation between chronological and predicted age (Fig. 1f ),
suggesting that TBI/HSCT could be responsible for the
accelerated epigenetic aging in T cell. When we com-
pared the methylation levels on three specific CpG sites
used to establish the Epigenetic-Aging-Signature, we
found a hypermethylation only on PDE4C in the TBI/
HSCT group (p > 0.05 for ASPA and ITGA, p < 0.01 for
PDE4C, Additional file 1: Figure S1c). Consistent with
the Epigenetic-Aging-Signature, transcriptomic analysis
of T cells showed that more than 10% of differentially
expressed genes belonged to the “innate and adaptive
immunity, cytokine, and chemokine” cluster of genes,
which constitutes genes previously reported to contrib-
ute to the aging signature of peripheral blood
(Additional file 1: Table S3A) [22]. The present results
support a role for cancer treatment in the accelerated
aging of T cell in cancer survivors.
Multiple reports have suggested an increased preva-
lence of inflammatory diseases in cancer survivors. We
thus investigated the presence of cardio-metabolic risk
factors in our cohort. Consistent with previous studies
[3, 7], CCS treated with TBI/HSCT had impaired
metabolic profile, including increased triglycerides and
reduced high-density lipoprotein cholesterol (HDL-C)
levels (p < 0.05, Table 1). Importantly, these changes
were not due to a difference in age, age at diagnosis,
body mass index (BMI), or waist-to-hip ratio (p > 0.05,
Table 1). The level of insulin resistance was also higher
in the TBI/HSCT group (p = 0.04, Table 1), while fasting
blood glucose and insulin levels also tended to be higher
in that group (p = 0.1 and p = 0.07 respectively; Table 1).
These results confirm that CCS, in particular those who
received TBI/HSCT, are at increased cardio-metabolic
risks with a potential link with chronic inflammation.
Discussion
Our results suggest that cancer treatment stably re-
models the T cell epigenome at specific genes controllinginflammation and oxidative stress in CCS. Using various
markers of immune cell function and signaling pathways
regulating pro-inflammatory cytokines production, we
establish a link between T cell epigenetic remodeling
and low-grade inflammation in survivors, in particular
those who received TBI/HSCT. We identified that TBI/
HSCT is associated with accelerated aging and propose
a role for epigenetic changes in the elevated risk of age-
and inflammation-related diseases long after treatment
in CCS [23].
We found that CCS treated with TBI/HSCT are
characterized by systemic inflammation. The secretion
of cytokines by immune cells is regulated by epigenetic
mechanisms [24]. Our global DNA methylation analysis
of T cell from survivors supports a dramatic remodeling
of the epigenome after TBI/HSCT. Radiation-induced
long-term epigenetic changes have been reported in
cultured human keratinocytes and rodents [25, 26] and
could mediate the imprinting of a long-term “memory”
of the radiation insult, potentially affecting immune cell
function. HSCT has also been associated with an inflam-
matory response, although limited information regarding
its long-term effect has been reported [16]. Nonetheless,
it can be hypothesized that even sub-clinical levels of
graft-versus-host disease could have contributed to the
immune changes reported here. We have previously
shown that the epigenome of lymphocytes is linked to
environmental influences, notably nutritional [27, 28].
Epigenetic mechanisms including changes in DNA
methylation, histone modifications, or even miRNAs are
well-described as modulators of immune cell differenti-
ation and function [29, 30]. For example, differentiation
and polarized activation of T helper or cytotoxic cells
are controlled by global DNA methylation at particular
gene loci [31, 32]. Although we did not observe specific
changes at previously reported gene loci, we identified
several differentially methylated genes involved in critical
pathways controlling T cell differentiation or cytokine
production. It cannot be ruled out that by investigating
epigenetic changes in global CD4+ T cell, we might have
missed DNA methylation changes specific to effector,
memory, or regulatory T cell [31, 32]. In addition, these
T cell subtypes present different epigenetic signature [31,
Daniel et al. Clinical Epigenetics          (2018) 10:138 Page 9 of 1332]. Thus, our results could also suggest changes in the
distribution of T cell subsets.
We found a greater frequency of type 1 cytokine-
producing T cell in irradiated survivors, with these cells
showing higher activation of p38 MAP kinase pathway and
mTOR Complex 1 (mTORC1) signaling (S6 k1), poten-
tially through a bystander effect. Direct and indirect expos-
ure to ionizing radiation activate MAPKs (p38/JNK) and
the PI3K (phosphoinositide 3-kinase)/Akt/mTOR path-
ways [12, 33], and both p38 and mTORC1 are critical for
Th1 polarization and type 1 cytokines production [34, 35].
The over-activation of both p38 and mTORC1 is consist-
ent with the greater frequency of Th1 cells and the higher
levels of pro-inflammatory cytokines in survivors who
received TBI/HSCT. The response to radiation involves
the mobilization of immune cells and pro-inflammatory
cytokine production, although these immune changes usu-
ally resolve within hours to days upon exposure [36]. Simi-
larly, HSCT can be associated with an inflammatory
response, though the long-term consequences remain
unclear [16]. Delayed or chronic immune activation after
radiation has been reported in atomic bomb survivors
more than 50 years after exposure [37]. Impaired immune
function has also been reported up to 10 years following
radiation in long-term cancer survivors [15], although in
both cases, the molecular mechanisms were not identified.
Our results suggest that such immune changes could result
from an indirect effect of irradiation, potentially due to cir-
culating factors. This bystander effect has been previously
suggested as playing a key role in the adaptations following
irradiation [12]. Although we could not identify specific
factors driving the epigenetic remodeling and altered im-
mune function, it is likely that such factors might contrib-
ute to these phenomena [12]. We can speculate that the
observed changes in the T cell methylome and T cell func-
tion could be involved in the perpetuation of the cancer
treatment-induced pro-inflammatory programming. Limi-
tations associated with our in vitro model to investigate the
direct effect of irradiation, in particular the absence of the
regulator of the Akt/mTOR pathway Phosphatase and
TENsin homolog (PTEN) in Jurkat cells, forces us to cau-
tion when interpreting our results using this cell system.
Further work is needed using other cell models to fully
clarify the influence of irradiation on the epigenome.
Inflammation and oxidative stress are associated with
several processes involved in aging [38]. Recently,
changes in both the epigenome and the transcriptome of
circulating leukocytes have been linked to the biological
(rather than chronological) age of an individual [22, 39].
A marked remodeling of the epigenome encompassing
global DNA hypomethylation and gene-specific hyper-
methylation at particular loci has been reported during
aging [38], consistent with the hypomethylation we ob-
served in T helper cells at the global DNA level. At thegene level, particular loci or even CpG sites have been
identified as predictive markers of biological age [39]
and allowed us to identify an increased predicted bio-
logical age in cancer survivors. Several components of
the radiation response can contribute to accelerated
aging or inflammatory diseases, including low-grade sys-
temic inflammation, activation of MAPK/mTOR signal-
ing, epigenetic remodeling, or oxidative stress [12, 33,
38, 40, 41]. In the present study, we identified the pres-
ence of such disturbances in cancer survivors more than
10 years post-treatment, which potentially explains the
accelerated aging reported in this population [23]. We
and others have previously shown that both reactive
oxygen species and pro-inflammatory cytokines can
affect DNA methylation [42, 43]. We can speculate that
the initial inflammatory response and oxidative burst in
response to treatment might have contributed to the epi-
genetic remodeling of immune cells, although the timing
and nature of the events that might have led to this
“long-term memory” are still to be unraveled. These
changes in the T cell methylome might be involved in
the perpetuation of the pro-inflammatory programming
contributing to the early onset of cardio-metabolic com-
plications in cancer survivors.Conclusions
Improvements in childhood cancer survival are associated
with higher prevalence of treatment-associated diseases
later in life, notably of age-related conditions including car-
diometabolic diseases. We identified low-grade inflamma-
tion and altered immune cell function in survivors treated
with TBI/HSCT. This was associated with a dramatic
remodeling of the T cell epigenetic signature and features
of accelerated epigenetic aging. These immune changes
could account for the increased risk of inflammatory and
age-associated diseases later in life. A greater understand-
ing of the mechanisms by which cancer treatments affect
the epigenome of immune cells may help to decrease
long-term complications in cancer survivors.Methods
Participants
We recruited 44 childhood cancer survivors, diagnosed
between 0 and 18 years, in full remission for more than
5 years and 16 years old and older at the time of enrol-
ment. Survivors who had experienced graft-versus-host
disease were not included in this study. This project was
approved by the Human Research Ethics Committee
(UNSW Sydney, HREC-10/017) and performed in accord-
ance with Helsinki Declaration procedures. The nature of
the project was explained and participants provided in-
formed consent. Participants had received chemotherapy
only (non-IRR) or a combination of chemotherapy with
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medical history were recorded and BMI calculated.Biological analyses
Fasting blood samples were collected and stored at − 80 °C.
Serum insulin (Immulite 2000, Diagnostic Products Cor-
poration, CA, USA), glucose levels, HDL-C, low-density
lipoprotein cholesterol (LDL-C), and triglycerides were
measured (LX20 analyzer, Beckman Coulter, CA, USA),
and the insulin resistance index was calculated (Homeosta-
sis Model Assessment, HOMA-IR) [44]. Systemic cytokine
levels including IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IFN-γ,
TNF-α, and granulocyte-monocyte colony stimulating
factor were measured (Bio-Plex Pro Human Cytokine Th1/
Th2 Assay, Bio-Rad Laboratories Inc., Australia,
Intra-assay CV: 7–12% and Inter-assay CV: 6–10%). Re-
sults were reported only for cytokines that were detectable
in more than 30% of the participants.Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated
from whole blood and cryopreserved [28]. PBMCs were
thawed, left to recover overnight, and mitogen-stimulated
for 6 h (2 μg/ml phorbol 12-myristate 13-acetate/ionomy-
cin, Sigma-Aldrich, Australia), with the addition of monen-
sin (BioLegend, CA, USA) after 2 h. PBMCs were then
fixed (2% paraformaldehyde), stained for dead cells (eth-
idium monoazide bromide, Sigma-Aldrich), and perme-
abilized in ice-cold methanol. Cells were then stained using
CD4-V500, CD-PE-Cy7, IL-4-PE, IFN-γ-Pacific blue (BD
Biosciences, Australia), and phosphorylated pAkt-Ser473-
AF647 (BD Biosciences), pS6k1-AF488, pJNK-AF488, and
phosphorylated p38-AF647 (Cell Signaling Technology,
MA, USA). PBMCs were analyzed on FACS CantoII (BD
Biosciences), with data post-compensated and analyzed
using FlowJo (Tree Star Inc., OR, USA). Results were
expressed as percentage of IL-4+/IFN-γ+ cells or normal-
ized median fluorescence intensity for pAkt, pS6k1, pJNK,
and p-p38 in CD4+ and CD8+ cells.In vitro and co-culture models
Jurkat cells (Clone E6–1, ATCC, VA, USA) were irradi-
ated with doses of 0, 1, 3, or 6Gy (Xrad 320, Precision
X-ray Inc., CT, USA) and left to recover for 24 h. At
days 1, 14, and 28, post-irradiation cells were mitogen-
stimulated and analyzed by flow cytometry as described
above. Adipocytes (3 T3-L1, CL-173, ATCC) were irradi-
ated with doses of 0, 1, 3, and 6Gy and left to recover
for 24 h prior to the collection of culture media. PBMCs
from six young healthy donors were mitogen-stimulated
in conditioned media from irradiated adipocytes and
analyzed by flow cytometry as described above.Protein sample preparation and mass spectrometry
Plasma samples (14ul) from childhood cancer survivors
were depleted from the 14 most abundant proteins (Sigma
Seppro IgY14 Spin columns). Depleted plasma sample
and conditioned media from cultured fibroblasts and fi-
broblasts differentiated into adipocytes (only 0/3Gy and at
24 h/7 days post-irradiation) were processed as previously
described with slight modifications (see “Additional file 1”)
[45]. A survey scan m/z 350–1750 was acquired in the
Orbitrap and lock mass enabled with data-dependent tan-
dem MS analysis performed using a top-speed approach
(cycle time of 2 s). MS2 spectra were fragmented by HCD
activation mode and the ion trap was selected as the mass
analyzer. Peak lists were generated using Mascot Daemon
and submitted to Mascot (version 2.5.1, Matrix Science).
Label-free quantitation was carried out using MaxQuant
(version 1.5.6.5) and Perseus (version 1.5.6.0) and pathway
analysis using G-Profiler.
Epigenetic analyses
Global DNA methylation
Global DNA methylation was measured in PBMCs, using
surface markers (CD3-PE, CD4, or CD21-APC, CD8, or
CD14-PerCP, BD Biosciences) and anti-5-methylcytidine
antibody (AbD Serotec, Bio-Rad) conjugated to AF488
(Zenon AF488 Mouse IgG1 labeling kit, Life Technolo-
gies, Australia) as previously described [28].
Gene-specific methylation
PBMCs were sorted on Influx Cell Sorter (BD Biosciences)
using specific surface markers (CD4 and CD19/
CD20-BV421, CD8-BV510, CD3-FITC, CD56-PE-CF594,
CD45-PerCP-Cy5.5, and CD14-APC, BD Biosciences).
Cells were then lysed before DNA/RNA extraction
(AllPrep DNA/RNA/miRNA Universal kit on QIAcube,
Qiagen, Australia). CD4+ T cell DNA was processed using
reduced representation bisulfite sequencing with minor
changes [46]. Genomic DNA was fragmented by overnight
incubation with Msp1 restriction enzyme and adenylated
with dATP and Klenow DNA polymerase (3′ to 5′ exo
minus) before ligation to TruSeq adapters (Illumina, CA,
USA). Twelve ligated samples were pooled and processed
for bisulfite conversion using EZ DNA methylation kit
(Zymo Research, CA, USA). Libraries were enriched by
PCR, purified with AMPure beads, and sequenced on a
HiSeq (50 bp single-end sequencing, Illumina, Danish
National High-Throughput DNA Sequencing Centre,
Denmark). Preprocessed reads were aligned to hg38 with
Bismark [47], and differential methylation was analyzed
with MethylKit [48]. All regions were annotated with the
Bioconductor package ChIPseeker [49]. CpGs with more
than 25% methylation change and q value < 0.01 were in-
cluded for further analysis. Gene Ontology (GO) analysis
was performed using a hypergeometric test on individual
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cell-specific enhancers were downloaded from SlideBase
[51, 52] and lifted to hg38 using the UCSC liftOver tool
[53], before counting overlaps with DMRs.Epigenetic-Aging-Signature
DNA methylation was measured on sorted CD8+ T
cell at three specific CpG sites (ASPA, ITGA2B, and
PDE4C) by bisulfite pyrosequencing. Beta values were
then used in a multivariate model to estimate the
predicted biological age as previously described [39].Whole transcriptome sequencing
RNA from CD4+ T cell was sequenced following
standard protocol (Truseq Stranded total RNA proto-
col, Illumina). After depletion of ribosomal RNA and
fragmentation, cDNA synthesis was performed on the
first strand, followed by second strand synthesis.
cDNA was cleaned using AMPure beads, adenylated
and then ligated to adapters. Following an additional
beads cleanup, DNA fragments were enriched by
PCR and subjected to a final beads cleanup. Libraries
were sequenced on a HiSeq (100 bp single-end
sequencing, Illumina, Danish National High-
Throughput DNA Sequencing Centre). Reads were
aligned to hg38 using Rsubread aligner, and the num-
ber of reads aligning with Gencode (version 23) was
counted with featureCounts [54]. Genes with less
than 1 RPKM in half the samples were excluded. Dif-
ferential expression was calculated with edgeR [55]
using glmFit/glmLRT functions and tagwise disper-
sion, with correction for multiple testing using the
Benjamini–Hochberg procedure. GO analysis was per-
formed using GOrilla [56], and scatter plots were
generated with REVIGO [50].Statistical analysis
Data are expressed as mean +/− standard deviation and
analyzed using SPSS Statistics (IBM, NY, USA). Nor-
mality of the distribution was tested using the Skewness
and Kurtosis tests and anthropometric data, biological
markers, cytokines levels, T cell polarization, and global
DNA methylation or predicted age were compared
using Student t test or Mann-Whitney U test. A
chi-square test was used to compare the frequencies
between the two groups. The effect of irradiation/mito-
gen stimulation on intracellular signaling was tested
using two-way ANOVA for repeated measures or a
combination of Friedman’s ANOVA and Mann-
Whitney U test. Correlation levels were tested using
the Pearson or Spearman tests.Additional file
Additional file 1: Figure S1. CD8+ cells polarized activation in
childhood cancer survivors (CCS). Figure S2. Intracellular signaling
pathways involved in T cell polarization in response to direct and indirect
irradiation. Figure S3. Intracellular signaling pathways and polarized
activation in CD8+ cells exposed to conditioned media from irradiated
adipocytes. Table S1. Differentially Methylated Genes. Table S2. Gene
Ontology from differentially methylated genes. Table S3. a. Genes
differentially expressed. b. Gene Ontology terms from differentially
expressed genes. Table S4. Proteins identified in the supernatant of
irradiated fibroblasts. (ZIP 4590 kb)
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